A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal

Detalhes bibliográficos
Autor(a) principal: Silva, Rufino
Data de Publicação: 2017
Outros Autores: Goncalves, Carla, Meireles, Angela, Teixeira, Carla, Rosa, Paulo, Monteiro-Grillo, Manuel, Canelas, Joaquim, Carneiro, Angela, Flores, Rita
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/108081
https://doi.org/10.20344/amp.8217
Resumo: Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice. Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent. Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively. Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved. Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.
id RCAP_99d5a9c357183c604fc9edcbf1c4eb3e
oai_identifier_str oai:estudogeral.uc.pt:10316/108081
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from PortugalAnálise retrospetiva sobre a utilização em contexto real do ranibizumab em doentes com degenerescência macular da idade exsudativa em PortugalPortugalRanibizumabVisual AcuityWet Macular DegenerationAcuidade VisualDegenerescência Macular ExsudativaFactores de TempoPortugalRanibizumabAgedAngiogenesis InhibitorsFemaleHumansMalePortugalRanibizumabRetrospective StudiesWet Macular DegenerationIntroduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice. Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent. Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively. Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved. Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.Introdução: A terapeutica com anti-factor de proliferação endotelial vascular revolucionou o tratamento da degenerescência macular da idade exsudativa; no entanto, é importante monitorizar o uso em contexto real do ranibizumab e os resultados associados ao tratamento na prática clínica corrente. Material e Métodos: Este foi um estudo observacional, retrospetivo, para monitorizar os resultados de dois anos, após o tratamento com ranibizumab para a da degenerescência macular da idade exsudativa em Portugal. Os doentes tratados entre janeiro de 2009 e dezembro de 2009 foram avaliados retrospetivamente. Todas as decisões foram tomadas pelo médico responsável pelo tratamento, em conformidade com a respetiva prática clínica corrente. A avaliação primária foi a alteração média na melhor acuidade visual corrigida utilizando a tabela ETDRS (Early Treatment of Diabetic Retinopathy Study) ou Snellen equivalente. Resultados: Foi analisado um total de 128 doentes com degenerescência macular da idade exsudativa (idade média de 79,4 anos; média de acuidade visual de 54,2 letras). A alteração média na melhor acuidade visual corrigida desde a situação basal foi de -1,6 letras (n = 82) no ano um e -5,1 letras (n = 72) no ano dois. O número médio de injeções de ranibizumab foi de 3,8 (ano um) e 1,6 (ano dois). Em média, os doentes tiveram entre 8,6 e 5,0 consultas e foi utilizada a tomografia de coerência ótica em 75,0% dos doentes no ano um e em 56,3% dos doentes no ano dois, respetivamente. Discussão: Apesar do número de consultas relativamente elevado, incluindo consultas de monitorização e de utilização de terapêutica guiada por tomografia de coerência ótica, foram administradas poucas injeções e não houve melhoria na acuidade visual. Conclusão: Em Portugal, num contexto real, estes achados indicam que o tratamento consoante as necessidades resultou numa dosagem insuficiente. Essas limitações também podem estar associadas ao número crescente de doentes, o que resulta numa saturação clínica.Ordem dos Medicos2017-06-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/108081http://hdl.handle.net/10316/108081https://doi.org/10.20344/amp.8217eng1646-07580870-399XSilva, RufinoGoncalves, CarlaMeireles, AngelaTeixeira, CarlaRosa, PauloMonteiro-Grillo, ManuelCanelas, JoaquimCarneiro, AngelaFlores, Ritainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-09T11:22:24Zoai:estudogeral.uc.pt:10316/108081Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:24:20.973226Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
Análise retrospetiva sobre a utilização em contexto real do ranibizumab em doentes com degenerescência macular da idade exsudativa em Portugal
title A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
spellingShingle A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
Silva, Rufino
Portugal
Ranibizumab
Visual Acuity
Wet Macular Degeneration
Acuidade Visual
Degenerescência Macular Exsudativa
Factores de Tempo
Portugal
Ranibizumab
Aged
Angiogenesis Inhibitors
Female
Humans
Male
Portugal
Ranibizumab
Retrospective Studies
Wet Macular Degeneration
title_short A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
title_full A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
title_fullStr A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
title_full_unstemmed A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
title_sort A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
author Silva, Rufino
author_facet Silva, Rufino
Goncalves, Carla
Meireles, Angela
Teixeira, Carla
Rosa, Paulo
Monteiro-Grillo, Manuel
Canelas, Joaquim
Carneiro, Angela
Flores, Rita
author_role author
author2 Goncalves, Carla
Meireles, Angela
Teixeira, Carla
Rosa, Paulo
Monteiro-Grillo, Manuel
Canelas, Joaquim
Carneiro, Angela
Flores, Rita
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Rufino
Goncalves, Carla
Meireles, Angela
Teixeira, Carla
Rosa, Paulo
Monteiro-Grillo, Manuel
Canelas, Joaquim
Carneiro, Angela
Flores, Rita
dc.subject.por.fl_str_mv Portugal
Ranibizumab
Visual Acuity
Wet Macular Degeneration
Acuidade Visual
Degenerescência Macular Exsudativa
Factores de Tempo
Portugal
Ranibizumab
Aged
Angiogenesis Inhibitors
Female
Humans
Male
Portugal
Ranibizumab
Retrospective Studies
Wet Macular Degeneration
topic Portugal
Ranibizumab
Visual Acuity
Wet Macular Degeneration
Acuidade Visual
Degenerescência Macular Exsudativa
Factores de Tempo
Portugal
Ranibizumab
Aged
Angiogenesis Inhibitors
Female
Humans
Male
Portugal
Ranibizumab
Retrospective Studies
Wet Macular Degeneration
description Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice. Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent. Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively. Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved. Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.
publishDate 2017
dc.date.none.fl_str_mv 2017-06-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/108081
http://hdl.handle.net/10316/108081
https://doi.org/10.20344/amp.8217
url http://hdl.handle.net/10316/108081
https://doi.org/10.20344/amp.8217
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1646-0758
0870-399X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Ordem dos Medicos
publisher.none.fl_str_mv Ordem dos Medicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134128541532160